Home › Trials › NCT07116876

Matrion placental membrane for diabetic foot ulcers

An Open-Label Trial to Assess the Clinical Effectiveness of Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

Not applicable Interventional LifeNet Health · NCT07116876

This study will test if Matrion, a sterilized decellularized placental membrane graft, heals diabetic foot ulcers in adults with diabetes better than standard wound care.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment120 (estimated)
Ages21 Years to 80 Years
SexAll
SponsorLifeNet Health Industry-sponsored
Locations18 sites (Tucson, Arizona and 17 other locations)
Trial IDNCT07116876 on ClinicalTrials.gov

What this trial studies

Participants with a single full-thickness diabetic foot ulcer below the ankle will receive either a Matrion graft application or conventional wound dressing per the study protocol and be followed for wound-healing outcomes. Matrion is derived from donated human amniotic and chorionic tissue that has been decellularized and terminally sterilized to be acellular and suitable for surgical use. Eligible wounds must be between 1 and less than 25 cm2 in area, no deeper than 9 mm, present for at least 30 days, and meet Wagner grade 1 or 2 criteria. The trial is being conducted at multiple clinical sites in Arizona and California using graft application and standard dressing interventions to compare healing results.

Who should consider this trial

Good fit: Adults aged 21–80 with type 1 or type 2 diabetes on a stable diabetes regimen who have a single full-thickness diabetic foot ulcer (1–<25 cm2, ≤9 mm deep) below the ankle present for at least 30 days and classified as Wagner grade 1 or 2 are ideal candidates.

Not a fit: Patients with wounds outside the size or depth limits, multiple target ulcers, or those with deeper/complicated wounds such as osteomyelitis or extensive infection are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the product could speed wound closure and reduce complications such as infection and the need for more invasive procedures.

How similar studies have performed: Other amniotic or placental membrane products have shown promise for diabetic foot ulcers in prior trials, although results vary by product and processing and fully decellularized, terminally sterilized membranes are less extensively studied.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

To be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below:

1. Be male or female and aged between 21 and 80 years at the time of informed consent
2. Have a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association and have been on a stable anti-diabetic treatment regimen for at least 30 days before the baseline visit.
3. Have full-thickness wound of the lower extremity, below the ankle
4. Have a single target ulcer
5. Have a wound with an area greater than or equal to 1cm2 and less than 25 cm2 with a depth less than or equal to 9 mm
6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

   * Grade 1: superficial diabetic ulcer involving the full skin thickness but not underlying tissues
   * Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess or osteomyelitis
7. Have an absence of infection based on Infectious Disease Society of America criteria (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
8. Have an adequate circulation to the affected lower extremity, defined as at least one of the criteria within the previous 60 days:

   * Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mm Hg
   * Ankle-brachial index (ABI) ranging from 0.8 to 1.2
   * At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
9. Have the ability to comply with off-loading and dressing change requirements
10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
11. Have provided written authorization for use and disclosure of protected health information
12. Have a life expectancy of greater than 6 months

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

1. Be pregnant or lactating
2. Subjects with a target wound \<30 days old at Screening whose wound area has decreased in size ≥50% between the Screening and Baseline Visits (assessed at Baseline/Visit 2)
3. Have a circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit (assessed at Screening/Visit 1 for subjects with labs collected \<30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
4. Have a serum creatinine concentration of 3.0 mg/dL or greater within 30 days prior to screening (assessed at Screening/Visit 1 for subjects with labs collected \<30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
5. Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin
6. Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol
7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the Screening Visit
8. Need for any additional concomitant dressing material other than the ones approved for this study
9. Have clinical signs of an infection at the study ulcer site (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
10. Have the inability to tolerate an off-loading boot
11. Have a known or suspected disease of the immune system
12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease
13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the Baseline Visit
14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement (assessed at Baseline/Visit 2)
15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the Baseline Visit
16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening (assessed at Screening/Visit 1 if subject had labs collected \<30 days of screening; assessed at Baseline/Visit 2 if subject had labs collected at screening)
17. Have active Charcot disease
18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Where this trial is running

Tucson, Arizona and 17 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Diabetic Foot UlcerLower Extremitydiabetic foot ulcerplacental membranelower extremity wounddecellularized placental membranefoot diseasesfoot ulcer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.